Gilead Sciences reported $1.9B in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
ALKERMES USD 261.1M 37.86M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Coherus Biosciences USD 5.67M 842K Jun/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Glaxosmithkline GBP 6.3B 143M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
J&J USD 15.38B 233M Sep/2026
Merck USD 6.16B 43M Sep/2026
Moderna USD 313M 33M Sep/2026
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Novartis USD 6.1B 116M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
United Therapeutics USD 201.9M 8.1M Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026